Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Crescent Biopharma (CBIO) Receivables - Other (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Receivables - Other for 11 consecutive years, with $78762.0 as the latest value for Q1 2025.

  • For Q1 2025, Receivables - Other fell 28.36% year-over-year to $78762.0; the TTM value through Mar 2025 reached $78762.0, down 28.36%, while the annual FY2023 figure was $175820.0, 22.08% up from the prior year.
  • Receivables - Other hit $78762.0 in Q1 2025 for Crescent Biopharma, up from $50255.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $444568.0 in Q1 2021 and bottomed at $1347.0 in Q4 2021.
  • Average Receivables - Other over 5 years is $121182.9, with a median of $100138.5 recorded in 2022.
  • On a YoY basis, Receivables - Other climbed as much as 10591.61% in 2022 and fell as far as 98.93% in 2022.
  • Crescent Biopharma's Receivables - Other stood at $1347.0 in 2021, then skyrocketed by 10591.61% to $144016.0 in 2022, then increased by 22.08% to $175820.0 in 2023, then plummeted by 71.42% to $50255.0 in 2024, then soared by 56.72% to $78762.0 in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $78762.0, $50255.0, and $76710.0 for Q1 2025, Q3 2024, and Q2 2024 respectively.